Loading…
← CockpitCompetitor Analysis › SOPH Sophia Genetics SAOpen in the cockpit ↗

Sophia Genetics SASOPHCompetitor analysis, valuation and peers

United States · USD·Information Technology›Packaged Software
Momentum strong 74
Mkt cap
$608M
US dollars, full cap
Free float
73%
of shares outstanding
$/day
$4.69M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-170.2 pp
WACC 9.9%
Hurdle
n/a
no reverse DCF
Next earnings
123 days
9 Mar 2027
Close · USD$7.14
1D+7.8%
1W-6.4%
1M-2.2%
3M-6.9%
6M+38.6%
YTD+52.9%
1Y+58.0%
ATR %7.5%
Beta1.46
52w lowhigh20.5% off high

What Sophia Genetics does

Employees: 415

Sophia Genetics at a glance

Size Sophia Genetics (SOPH) is a United States Information Technology company (Packaged Software) with a market value of $608M, the 2575th largest of 3,117 United States companies the cockpit tracks. Shares closed at $7.14 on 6 Nov 2026.

Performance Over six months the shares gained 38.6%, against -23.0% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.

Growth Revenue grew 24.1% over the last twelve months (peer median +19.0%); the operating margin is -79.9% (peer median 2.1%).

Valuation It trades at 6.3× enterprise value to sales against a peer median of 4.7× (9th most expensive of 20).

Capital Return on invested capital runs 170.2 points below its cost of capital (9.9% WACC).

Short interest Short interest is 1.2% of the free float (15 Oct 2026).

Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015011 May 202611 Aug 20266 Nov 2026SOPH 149Peer median 74
Six months, rebased to 100: Sophia Genetics against the median of its 20 peers (local-currency closes).

Sophia Genetics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$91.0M$77.3M$65.2M$62.4M$47.6M
Revenue growth—+19%+4%+31%—
Gross profit$60.4M$47.8M$38.9M$36.7M$26.8M
EBITDA-$61.7M-$61.4M-$58.9M-$68.6M-$83.9M
Net income-$81.1M-$79.0M-$62.5M-$79.0M-$87.4M
Free cash flow-$45.1M-$38.6M-$43.1M-$50.1M-$74.2M
Capital expenditure$10.2M$8.62M$8.18M$9.23M$10.4M
Total debt$61.0M$63.0M$30.0M$18.6M$16.7M

Quarterly statements and history in the cockpit →

Sophia Genetics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+200%+400%+600%-25%0%+25%+50%688039TXT66873993RCATHQ278A600212300299300380SOPH6-month return →1-month return →
Up and to the right = strong over both horizons. Sophia Genetics is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%0×50×100×688039TXT6687RCAT003007301213445680SOPHRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sophia Genetics is the large dot.

Sophia Genetics competitors and peer comparison

How Sophia Genetics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sophia Genetics against its 20 peers (data as of 6 Nov 2026)
MeasureSOPHPeer medianRank in peer set
1-month return-2.2%-7.8%5th highest of 21
6-month return+38.6%-23.0%2nd highest of 20
Distance from 52-week high-20.5%-44.1%3rd highest of 21
Revenue growth (TTM)+24.1%+19.0%8th highest of 20
Operating margin-79.9%2.1%3rd lowest of 20
EV / Sales6.3×4.7×9th most expensive of 20
ROIC minus cost of capital-170.2 pp-8.9 pplowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Sophia Genetics SOPHUnited States$608M+39%+24%-80%6.3×n/an/a
Hangzhou Arcvideo Technology 688039.SSChina$609M-13%+1%-48%12.5×n/an/a
TXT e-solutions TXT.MIItaly$610M+29%+22%6%1.5×10.3%+41.8%
JST 6687.HKHong Kong$603M-28%+26%11%1.1×-11.9%+30.3%
PKSHA Technology 3993.TJapan$602M-8%+74%16%2.5×16.6%+24.1%
Red Cat RCATUnited States$617M-61%+693%-150%4.3×n/an/a
Horizon Quantum HQUnited States$617M+14%n/an/an/an/an/a
Beijing ZZNode Technologies 003007.SZChina$617M-23%+64%20%6.8×n/an/a
Terra Drone 278A.TJapan$618M+564%+14%-26%17.8×n/an/a
Cognyte Software CGNTUnited States$597M-27%+28%5%1.3×22.2%-2.0%
RaySearch Laboratories RAY-B.STSweden$618M+1%+3%19%4.7×7.3%+15.6%
Zhejiang TOP Cloud-agri Technology 301556.SZChina$620M-34%-14%13%7.7×30.7%+14.0%
Gresgying Digital Energy Technology 600212.SSChina$594M-34%-8%-6%3.3×23.5%+38.2%
UISEE Technologies (Beijing) 1511.HKHong Kong$593Mn/a+24%-71%11.2×n/an/a
Fuchun Technology 300299.SZChina$623M-2%+3%2%10.8×54.9%-4.8%
Shenzhen Sinovatio Technology 002912.SZChina$592M-2%+7%-10%4.1×n/an/a
Sansec Technology 688489.SSChina$590M-13%+18%-7%5.5×n/an/a
Shanghai Amarsoft Information & Technology 300380.SZChina$628M-30%-2%4%3.8×n/an/a
Sichuan Discovery Dream Science & Technology 301213.SZChina$633M-26%+34%2%19.9×n/an/a
Curiox Biosystems 445680.KSSouth Korea$577M-55%+37%-245%134.2×n/an/a
Mingchen Health 002919.SZChina$640M-33%+19%-5%2.4×27.2%+17.5%

Questions

Which companies are Sophia Genetics's closest peers?
The cockpit's peer set: Hangzhou Arcvideo Technology (688039.SS), TXT e-solutions (TXT.MI), JST (6687.HK), PKSHA Technology (3993.T), Red Cat (RCAT), Horizon Quantum (HQ), Beijing ZZNode Technologies (003007.SZ), Terra Drone (278A.T).
Is Sophia Genetics expensive compared with its peers?
On ev / sales it trades at 6.3× against a peer median of 4.7×, 9th most expensive of 20 in its peer set.
How has Sophia Genetics stock performed?
Over six months to 6 Nov 2026 the shares returned +38.6% against -23.0% for the median peer; over one year +58.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.